This Issue at a Glance

Silva et  al (p. 57) evaluated the efficacy and safety of a treat and extend (T&E) regimen versus a monthly regimen of ranibizumab 0.5 mg in patients with neovascular age-related macular degeneration (nAMD). They conducted a 12-month, Phase IIIb, multicenter randomized interventional study of 650 patients with newly diagnosed nAMD enrolled between December 2013 and November 2015 at 90 centers across 18 countries. The researchers found that patients made similar rapid gains in best-corrected visual acuity under both the T&E and monthly regimens.
Source: Ophthalmology - Category: Opthalmology Authors: Tags: This issue at a glance Source Type: research